Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Transarterial Epirubicin Chemotherapy in Sinonasal Adenoid Cystic Carcinoma
NCT07320508Phase 2Recruiting
- Sponsor
- Eye and ENT Hospital of Fudan University
- Start
- Jan 2026
- Primary completion
- Dec 2027
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of epirubicin in adenoid cystic carcinoma (ACC), sponsored by Eye and ENT Hospital of Fudan University. Primary endpoints: Objective Response Rate at 12 weeks, Progression-Free Survival at 2 years and 1 more. Started Jan 2026; status: recruiting.
02
Drugs
epirubicin
03
Conditions
adenoid cystic carcinoma (ACC)
Beyond the preview
Go deeper on NCT07320508.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07320508.